A Case of Tuberculous Arthritis Following the Use of Etanercept
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Etanercept is a tumor necrosis factor (TNF) inhibitor that has been used for the treatment of chronic inflammatory diseases including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Because of its immunosuppressive activity, opportunistic infections have been noted in treated patients, most notably caused by Mycobacterium tuberculosis. Tuberculosis may present in an extrapulmonary or disseminated form. Since TNF-α inhibitors have been used in Korea, a few cases of TNF-α inhibitor associated tuberculosis have been described. However, tuberculous arthritis has not been previously reported. We describe a case of tuberculous arthritis in a 57-year-old woman with rheumatoid arthritis who was treated with etanercept.
Abstract
Etanercept is a tumor necrosis factor (TNF) inhibitor that has been used for the treatment of chronic inflammatory diseases including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Because of its immunosuppressive activity, opportunistic infections have been noted in treated patients, most notably caused by Mycobacterium tuberculosis. Tuberculosis may present in an extrapulmonary or disseminated form. Since TNF-α inhibitors have been used in Korea, a few cases of TNF-α inhibitor associated tuberculosis have been described. However, tuberculous arthritis has not been previously reported. We describe a case of tuberculous arthritis in a 57-year-old woman with rheumatoid arthritis who was treated with etanercept.
참고문헌 (21)
- Papadakis KA, "Tumor necrosis factor: biology and therapeutic implications", Gastroenterology, 119, pp.1148~1157 (2000)
- Algood HM, "Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis", Clin Infect Dis, 41(3), pp.s189~s193 (2005)
- Roach DR, "Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection", J Immunol, 168, pp.4620~4627 (2002)
- Taylor PC, "Anti-tumor necrosis factor therapies", Curr Opin Rheumatol, 13, pp.164~169 (2001)
- Ellerin T, "Infections and anti-tumor necrosis factor alpha therapy", Arthritis Rheum, 48, pp.3013~3022 (2003)
- Hamilton CD, "Infectious complications of treatment with biologic agents", Curr Opin Rheumatol, 16, pp.393~398 (2004)
- Gardam MA, "Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management", Lancet Infect Dis, 3, pp.148~155 (2003)
- Seong SS, "Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers", J Rheumatol, 34, pp.706~711 (2007)
- Listing J, "Infections in patients with rheumatoid arthritis treated with biologic agents", Arthritis Rheum, 52, pp.3403~3412 (2005)
- Winthrop KL, "Tuberculosis associated with therapy against tumor necrosis factor alpha", Arthritis Rheum, 52, pp.2968~2974 (2005)
- Lipsky PE, "Infliximab and methotrexate in the treatment of rheumatoid arthritis", N Engl J Med, 343, pp.1594~1602 (2000)
- Weinblatt ME, "A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate", N Engl J Med, 340, pp.253~259 (1999)
- Moreland LW, "Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial", Ann Intern Med, 130, pp.478~486 (1999)
- Mohan AK, "Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor", Clin Infect Dis, 39, pp.295~299 (2004)
- Gardam M, "Mycobacterial osteomyelitis and arthritis", Infect Dis Clin North Am, 19, pp.819~830 (2005)
- De Backer AI, "Imaging of extraspinal musculoskeletal tuberculosis", Eur J Radiol, 57, pp.119~130 (2006)
- Askling J, "Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden", Arthritis Rheum, 52, pp.1986~1992 (2005)
- Gomez-Reino JJ, "Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report", Arthritis Rheum, 48, pp.2122~2127 (2003)
- American Thoracic Society, "Targeted tuberculin testing and treatment of latent tuberculosis infection", Am J Respir Crit Care Med, 161, pp.s221~s247 (2000)
- Carmona L, "Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists", Arthritis Rheum, 52, pp.1766~1772 (2005)
- Furst DE, "Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents", Ann Rheum Dis, 61(2), pp.ii62~ii63 (2002)